Advice
Following a full submission
Cetuximab (Erbitux) is accepted for restricted use within NHS Scotland in combination with radiation therapy for the treatment of patients with locally advanced squamous cell cancer of the head and neck.
It is restricted to patients who are not appropriate for or unable to tolerate chemo-radiotherapy and who are of good performance status with no evidence of distant metastases. It is also restricted to use by specialists in the management of head and neck cancer.
Download detailed advice39KB (PDF)
Medicine details
- Medicine name:
- cetuximab 2mg/ml intravenous infusion (Erbitux)
- SMC ID:
- 279/06
- Indication:
- Locally advanced squamous cell cancer of the head and neck
- Pharmaceutical company
- Merck KGaA
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 July 2006